Background {#Sec1}
==========

Adolescent HIV patients face enormous difficulty in accessing HIV care services and they have worse treatment outcomes compared to other age groups \[[@CR1]\]. Few studies have investigated HIV-infected adolescents' progression through the HIV care pathway and have generally found their outcomes to be poor and worse than those for adults or young children. Specifically, rates of retention in care prior to antiretroviral therapy (ART) initiation, as well as retention and adherence to treatment after ART initiation, have been shown to be poor \[[@CR2], [@CR3]\]. Furthermore, a systematic review showed an average of only 62% of 12- to 24-year-olds achieved 95% or greater adherence to ART \[[@CR4]\]. Poor retention in care and adherence to ART will impact negatively on HIV/AIDS management and control, particularly in SSA as more than eight out of ten of the world's HIV-infected adolescents live in this region of the world \[[@CR5]\].

Poor adherence in adolescents may be connected to the unique psychological, social and health needs that are particular to the adolescent stage. Adolescence is sometimes accompanied by a desire for self-discovery, an emerging sense of autonomy, separation from caregivers and the assertion of independence, the quest for recognition and acceptance, all of which could lead to risk-taking behaviour \[[@CR6], [@CR7]\]. Evolving interventions to support retention of HIV-infected adolescents in care as well as ensuring their adherence to ART is essential not only to improve individual health for persons living with HIV but also to reduce transmission.

There is limited evidence on the effectiveness of service delivery interventions to support adolescents' linkage from HIV diagnosis to ART initiation, retention on ART and adherence to ART. A systematic review by Kim et al. identified a small number of studies that assessed the effectiveness of interventions to support adolescents' linkage from HIV diagnosis to ART initiation, retention on ART and adherence to ART \[[@CR4]\]. The systematic review concluded that offering individual and group education and counselling, financial incentives, increasing clinic accessibility and provision of specific adolescent-tailored services appear promising interventions and warrant further investigation.

The theoretical basis for conditional economic incentive and motivational interviewing (MI) {#Sec2}
-------------------------------------------------------------------------------------------

There is a theoretical foundation potentially underlying conditional economic incentives (CEI) for HIV treatment adherence. Micro- and behavioural-economic framework suggest that non-adherence is attributed to the perception of reduced utility due to out-of-pocket costs, side effects, perceived risks, delayed benefits, or other idiosyncratic reason \[[@CR8]\]. CEI, therefore, increases income when adherent, which in turn increases utility. Additionally, while people know that non-adherence to ART may risk treatment failure, opportunistic infections, etc., these events may occur in the future. Hence, CEI helps to bring the benefits (in monetary terms) much closer to the present.

In Nigeria, the conditional economic incentive has been applied in the Subsidy Reinvestment and Empowerment Programme (SURE-P) Maternal and Child Health (MCH) programme with the aim to increase demand and access to maternal and neonatal health services. In the programme, conditional cash transfer was used to encourage pregnant women from poor households to seek maternal and child health in public hospitals. Conditional cash transfer in a MCH context showed the capacity of having a significant effect on service uptake although the authors concluded that there is a need to track beneficiaries throughout the continuum of care \[[@CR9]\].

If appropriately implemented, CEI could help improve patients' adherence to HIV treatment in the short-term, while the incentives are in place. However, this does not necessarily create a lasting effect after the incentives are removed \[[@CR8]\]. Social and behavioural theoretical perspectives explain how behaviour can become habitual and sustained \[[@CR8]\]. For instance, the social context that supports satisfaction of basic needs support growth processes, including internally motivated behaviours \[[@CR10]--[@CR12]\]. Additionally, self-determination theory postulates that internalised motivation, rather than external incentives, is essential to long-term behavioural regulation. Therefore, interventions that help self-determination, such as MI, should be coupled to CEI in order to achieve a long-term adherence.

Motivational interviewing is a counselling method informed by self-determination theory and represents a general and practical approach for changing behaviours by enhancing and facilitating a patient's own internally motivated change process \[[@CR13]\]. MI recognises that responsibility for changing behaviour is assumed to lie within the individual, and ambivalence is recognised as a natural part of this change process \[[@CR8]\]. MI is different from other adherence counselling technique currently applied in HIV care due to three key elements: MI fosters collaboration between the counsellor and the client; MI evokes or draws out the client's ideas about change, and MI emphasises the autonomy of the client.

Study rationale {#Sec3}
---------------

Based on the systematic review by Kim et al. only one study has assessed the impact of financial incentive coupled with MI on treatment adherence of young adults \[[@CR14]\]. The study was conducted using a single-site, non-randomised and applied pre- and post-test design which is not deemed to have high internal validity. Some of the established threats to the internal validity of quasi-experimental design such as pre- and post-test design include history threat, maturation threat, testing threat, lack of blinding, instrumentation, regression to the mean, selection bias and drop out \[[@CR15]\].

Methods/design {#Sec4}
==============

Study objectives {#Sec5}
----------------

The main aim of the present study is to use the rigour of a randomised controlled trial (RCT) to evaluate the impact of financial incentive and MI on adolescents' linkage, retention and adherence to antiretroviral therapy and HIV care in Anambra State, Nigeria. A cost-effectiveness analysis alongside the cluster randomised trial will be conducted as a secondary aim to assess the cost per additional patient achieving viral suppression through the proposed intervention. In-depth interview (IDI) with all the healthcare providers in the intervention arm will be conducted at the end of the study to assess their perspective on the programme's feasibility. The main outcome will be measured at the level of an individual adolescent. Cluster randomisation is being chosen for practical reasons and to prevent treatment group contamination.

Trial design {#Sec6}
------------

The study will be a cluster randomised controlled trial. Clusters are HIV treatment hospitals in Anambra state. Hospitals (the clusters) will be matched by type of hospital (e.g. secondary or tertiary) and the paired units will be randomly assigned to the intervention or the control arm. The trial has two periods -- intervention period and post-intervention period. Each of these periods will run for a 1-year duration. Further details of the trial are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}. Figure [1](#Fig1){ref-type="fig"} shows the schedule of enrolment, interventions and assessments for the trial design.Table 1The World Health Organisation (WHO) trial registration datasetData categoryInformationPrimary registry and trial identifying numberThe Pan African Clinical Trials Registry: <https://pactr.samrc.ac.za/> (PACTR201806003040425)Date of registration in primary registry2 February 2018Source of monetary or material supportEuropean Developing Countries Clinical Trial Partnership (EDCTP)Primary sponsorNnamdi Azikiwe UniversityContact for public queriesoi.ekwunife\@unizik.edu.ngPublic titleConditional Economic Incentive and Motivational Interviewing to Improve Adolescents' Retention and Adherence to Antiretroviral Therapy and Care in South East Nigeria: a Cluster Randomised TrialScientific titleConditional Economic Incentive and Motivational Interviewing to Improve Adolescents' Retention and Adherence to Antiretroviral Therapy and HIV Care in South East Nigeria: a Cluster Randomised TrialCountry of recruitmentNigeriaHealth condition or problem studiesHIVInterventionsConditional economic incentive and motivation interviewingKey inclusion criteriaAll patients with HIV who had transitioned from pediatric stage to a young person/adult; age 10--19 years irrespective of CD4+ cell count; currently off antiretroviral therapy (ART) despite multiple attempts to restart; willing to restart therapy and sign a patient agreementStudy typeInterventionalDate of first enrolmentYet to commenceTarget sample size240Recruitment statusYet to commencePrimary outcomeHIV viral loadKey secondary outcomeCD4+ count, adherence to ART (measured using pill count) and adherence to appointment with hospitalTable 2Protocol for conditional economic incentivesStarted ARTVL response and attended for MIVoucher value (USD)Week 12VL \< 205.66 months suppressedSustained VL \< 202.89 months suppressedSustained VL \< 202.812 months suppressedSustained VL \< 205.6TotalVL suppression for 12 months16.8\
*ART* antiretroviral therapy, *VL* viral loadFig. 1Schedule of enrolment, interventions and assessments. \*CEI -- Conditional economic Incentives, MI -- Motivational interviewing

Trial sites selection {#Sec7}
---------------------

Twelve hospitals in Anambra State that offer HIV services will be randomly selected from all the hospitals in the state that provide HIV services. The hospitals included are registered by the National Agency for the Control of AIDS (NACA) to offer HIV services. The hospitals (the clusters) will be matched by type of hospital (e.g. secondary or tertiary) and the paired units will be randomly assigned to intervention or control.

Participants {#Sec8}
------------

Eligibility criteria for participants will include the following: all patients with HIV who had transitioned from pediatric stage to a young person/adult; 10--19 years irrespective of CD4+ cell count; initiated into HIV care and antiretroviral therapy for minimum of 6 months; currently off ART despite multiple attempts to restart; poor medication adherence (\< 95% adherence rate assessed through pill count or self-report); willing to restart therapy and sign a written informed consent (see Additional file [2](#MOESM2){ref-type="media"}).

Intervention {#Sec9}
------------

A structured adherence support scheme termed the 'Incentive Scheme' will be applied to the intervention hospitals while the control hospitals will receive usual care. The Incentive Scheme added to the usual care involves financial incentives linked to viral load (VL) combined with attendance for motivational interviewing (MI) with an adherence counsellor trained in MI techniques. (Table [2](#Tab2){ref-type="table"}) \[[@CR14]\]. Training on MI will be in accordance with an MI guide that covers key points for MI as well as examples and key insights to assessing patient risk, risk reduction counselling and inspiring behaviour change \[[@CR16]\]. Participants in hospitals randomised to usual care will receive the normal care obtainable in the HIV treatment hospitals. This typically involves monthly or bi-monthly scheduled hospital visit for medical examination, prescription refill and adherence counselling, bi-yearly VL assessment, and yearly CD4^+^ count analysis.

In addition to the usual care, participants in the intervention hospitals will receive MI at baseline and following initiation of ART, they will receive a gift voucher of US\$5.6 when VL \< 20 copies/mL at 12 weeks, a gift voucher of US\$2.8 if the VL remains suppressed for the next 3 months, and the next 6 months, and finally a gift voucher of US\$5.6 if the VL remains \< 50 copies/mL at 1 year. All incentives will be conditional not only on patients meeting their VL target but attending for MI. Those with VL higher than the thresholds will not receive the incentive. The potential maximum cumulative financial incentive is US\$16.8 if viral suppression is sustained for 12 months. The patient will have the liberty to withdraw from the scheme at any time point. Routine hospital data will be collected and outcomes will be assessed by changes in HIV VL and CD4+ count from baseline, at 12 months from enrolment and at 24 months to establish whether any benefit is seen from the intervention could be sustained when financial incentives cease. Each patient in the study will be assigned to a study nurse working in the HIV treatment hospital and they will be tracked with their mobile phone numbers.

Outcomes {#Sec10}
--------

The primary outcome for the trial will be the difference between groups in the proportion with HIV VL suppression (≤ 20 copies/mL) by 12 months and 24 months. The secondary outcome measure will include the average change in CD4+ count, adherence to ART (measured using pill count) and adherence to an appointment with the hospital for individual participants. Viral load analysis will be done using the COBAS TaqMan 96 and the Amplilink software.

Laboratory methods {#Sec11}
------------------

Ten millilitres of whole blood will be collected from each patient into a Vacutainer EDTA-plasma specimen from patients who were confirmed to be HIV-1 seropositive and receiving ART. These EDTA-plasma samples will be submitted to the virology laboratory of Nnamdi Azikiwe University Teaching Hospital for routine HIV-1 VL testing by the CAP/CTM v2.0 (Switzerland, 2016). EDTA-blood tubes will be centrifuged at 1450 *g* for 25 min prior to the plasma being separated into two aliquots in 2-mL cryovials and stored at − 88 °C in an ultralow freezer until the time of testing.

The VLs of these samples will be measured using the Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) commercial kits according to the manufacturer's instructions. The plasma HIV-1 ribonucleic acid (RNA) levels will be determined as copies/mL.

Viral RNA will be extracted automatically and transferred to the COBAS TaqMan system for amplification and detection. The CAP/CTM v2.0 will be implemented along with the COBAS AmpliPrep automated nucleic acid extractor and TaqMan 96 analyser. The quantification range of the CAP/CTM v2.0 is from 20 copies/mL to 10^7^ copies/mL. Each run will consist of tested samples and one high-positive control, one low-positive control, and one negative control from the kits. Results will be validated only when the three controls (NC, LPC and HPC) have passed per run. The CD4+ count analysis will be performed using the CD4+ easy count kit and the Partec CyFlow (Görlitz, Germany, 2014) in accordance with the manufacturer's instructions.

Sample size {#Sec12}
-----------

The sample size was calculated using a web-based sample size calculator of the UCSF Clinical and Translational Science Institute \[[@CR17]\]. The sample size calculation is based on the proportion of patients with VL suppression ≤ 20 copies/mL -- the main outcome measure. Based on a power of 80% and an α of 0.05 (two-sided), 63 patients per group will be needed to observe a 12% (assumed standard deviation of 24%) increase in the number of participants with VL suppression as previously reported \[[@CR18]\]. After adjustment for the cluster design, based on the assumed intracluster correlation coefficient of 0.047 and a fixed cluster per arm of six HIV treatment hospitals, the effective sample size increased to 120 patients per arm (i.e. a total of 240 participants). Due to potential attrition that could arise as a result of severe adverse events, treatment failures or the participant simply deciding to withdraw, we added three participants per hospital increasing the number of participants in each arm to 138 (i.e. a total of 276 participants). A fixed number of six clusters or hospitals per arm (i.e. 12 hospitals in total for the trial) were informed by the fact that only 12 hospitals in Anambra State offer comprehensive HIV services including HIV-adherence counselling and antiretroviral treatment services and these 12 hospitals have appreciable HIV client load. Each of the hospitals will, therefore recruit 23 participants.

Randomisation {#Sec13}
-------------

We will stratify each cluster unit (HIV treatment hospital) according to the type of clinic (secondary or tertiary). We will randomly allocate each HIV treatment hospital in each stratum into the intervention arm or the control arm. The randomisation schedule will be done using Research Randomiser, a web-based computer random-number generator \[[@CR19]\]. The randomisation schedule will be carried out by an independent person who is not part of the research team.

Statistical analysis {#Sec14}
--------------------

Statistical analysis will be conducted using IBM SPSS for Windows, Version 20 (IBM Corp, Armonk, NY, USA). As shown in Table [3](#Tab3){ref-type="table"}, descriptive statistics will be used to evaluate differences in demographic and clinical characteristics. Categorical variables will be expressed as frequencies or percentages and quantitative variables as means and standard deviations or medians and interquartile ranges. An intention-to-treat analysis will be conducted. A secondary per-protocol analysis will also be conducted. The latter will include only those participants who completed the treatment protocol originally allocated, providing results on the efficacy of the trial. If there is a significant difference between the intention-to-treat analysis and the per-protocol analysis, then the former will be reported. Comparison of dichotomous measurements between the intervention group and the control group will be conducted using the chi-square test (or Fisher's exact test) while comparison of the mean of continuous measurements between the intervention group and the control group will be conducted using an independent *t* test. A two-sided *p* value of 0.05 will be used to indicate statistical significance.Table 3Data analysis outlineStudy objectiveOutcome variableType of analysisObjective 1: effectiveness of interventionPrimary outcomeHIV viral load*χ*^2^ test or Fisher's exact testSecondary outcomesCD4+ countWithin group: paired-sample *t* tests or Wilcoxon signed-rank tests; between group -- Student's *t* test or Wilcoxon signed-rank testsAdherence to antiretroviral therapy (ART)*χ*^2^ test or Fisher's exact testAdherence to hospital appointmentWithin group: paired-sample *t* tests or Wilcoxon signed-rank tests; between group -- Student's *t* test or Wilcoxon signed-rank testsObjective 2: cost-effectiveness analysisCost-effectiveness of interventionIncremental cost-effectiveness ratioObjective 3: qualitative assessment of implementer's perspectiveProgramme implementer's perspectiveIn-depth interview (thematic content analysis)

Health resource implication and cost-effectiveness of the Incentive Scheme intervention will be assessed. Health resource use will be estimated from the health provider's perspective, i.e. all cost incurred for providing the Incentive Scheme by a health service provider. Resource use items will include items such as staff time, consumables, cost of financial incentive and equipment. All patient and family resources will be excluded. An activity-based costing method will be used to measure resource use. Data-capture questionnaires will be developed and sent to all the study personnel in the different study sites to record all their activities or resource use. Resource use items will then be multiplied by unit costs to determine a cost item. The entire cost item will be summed up and divided by the number of participants to determine the cost of the incentive scheme intervention per patient. A cost-effectiveness analysis alongside the cluster randomised trial will be conducted to assess the cost per additional patient achieving viral suppression through the proposed intervention. Incremental cost-effectiveness ratio (ICER) of Incentive Scheme over usual care will be calculated to determine the cost-effectiveness of the former.

A in-depth interview (IDI) with all the health providers in the intervention arm will be conducted at the end of the study to assess their perspective on the programme's feasibility. The IDI instrument to be used will be developed using the Pathfinder International Tool Series guideline on conducting IDI \[[@CR20]\]. During the interview, notes and audio digital recording will be taken and non-verbal and gestural cues will also be observed. All recorded data will be transcribed verbatim into English by the researcher and research assistant independently. A thematic content approach, guided by the Graneheim and Lundman framework, will be utilised for qualitative data \[[@CR21]\]. Responses from the IDIs will be read systematically through in order to indentify the meaning units. A meaning unit will be defined as a string of the text that expressed a single coherent thought, up to the point that the coherent thought changed \[[@CR22]\]. The meaning units will be coded using a describing cue related to the content of the meaning unit. Codes concerning the same subject will be grouped together into categories. The interview guide will be used as a point of departure for grouping information, deductively. Information obtained during the IDIs will be analysed and merged according to the codes and themes. Original data will be reassessed after analysis in order to detect any concepts or information that may be missed.

Recruitment and retention {#Sec15}
-------------------------

Eligible adolescents will be recruited by the study personnel in the trial site (e.g. trial physician or nurse). Each study participant will be assigned to a study nurse working in the HIV treatment hospital and they will be tracked with their mobile phone numbers.

Trial subject safety {#Sec16}
--------------------

The major risk envisaged in this trial will be exposure of the data of study participants. In order to mitigate this risk, patients' data will be treated with confidentiality. All personal data collection and processing will be carried out according to European Union (EU) and national legislation. Personal data collected are those necessary to establish the primary and secondary study outcomes. Unique identifiers and a password-protected database will be used to protect the personal information of the study participant. We will keep a written document with detailed information of the origin of all used human samples. All the study partners in the different study sites will receive training on procedures for handling pseudonymised data during study briefing/training. Training will be based on the principle of handling personal data elucidated in the 'Article 29 Data Protection Working Party'. To ensure the protection of personal data, the principal investigator (PI) (including data analyst) will receive only key-coded data.

Management of incidental findings and data monitoring {#Sec17}
-----------------------------------------------------

There is a chance of anticipatable incidental findings due to the increased number of laboratory testing (especially for those in the intervention arm) and closer monitoring. These anticipatable incidental findings include early detection of the following:Clinical failure: this is the presence of new or recurrent clinical event indicating severe immunodeficiency (WHO clinical stage 4 conditions) following 6 months of effective treatmentImmunological failure: this represents a CD4+ cell count fall to or below pre-treatment baseline value or persistent CD4+ levels below 100 cells/mm^3^ or 50% decline from on-therapy CD4+ cell count peak levelVirologic failure: this is the persistently detectable VL exceeding 1000 copies/mL (that is, two consecutive VL measurements within a 3-month interval, with adherence support between measurements) after at least 6 months of using antiretroviral drugs

Any such anticipatable incidental findings will be disclosed to the participants and their parents/legal guardians (for those less than 18 years). Management of these anticipatable incidental findings will be in accordance to the National Guidelines for HIV Prevention, Treatment and Care. This entails the following: providing adherence support and treating opportunistic infections in any suspected case of treatment failure; reassessing VL and.

CD4+ improvement after 3 months; and changing to second-line therapy in case of no improvement (i.e. VL \> 1000 copies/mL).

Any study-related adverse events (AEs) will be documented and reported to the Steering Committee/Data and Safety Monitoring Board. In the case of a serious adverse event (SAE), it will be reported to the Nnamdi Azikiwe University Ethics Committee within 14 days of the PI becoming aware of the event. SAE is defined as an untoward occurrence that (1) results in death; (2) is life-threatening; (3) requires hospitalisation or prolongation of existing hospitalisation; (4) results in persistent or significant disability or incapacity; (5) consists of a congenital abnormality or birth defect; and (6) is otherwise considered medically significant by the investigator.

Conditions in which expedited reporting will not apply include hospitalisation for (1) treatment which was pre-planned, or for a pre-existing condition not associated with any deterioration in condition and (2) treatment on an emergency, outpatient basis for an event not fulfilling any of the definitions of serious as given above and not resulting in hospital admission. Patients will be asked if any adverse events have occurred when they attend for any trial-related visits.

Trial management {#Sec18}
----------------

The Steering Committee will also serve as the Data and Safety Monitoring Board (DSMB). This committee is composed of two of the authors and three external, independent experts in HIV care, pharmacology and pharmacy ([Appendix](#Sec23){ref-type="sec"}). The Steering Committee/DSMB will provide overall supervision of the trial. Specifically, the committee will: (1) review and evaluate the accumulated study data every 6 months for patient safety and (2) study the conduct and progress of the trial and make appropriate recommendation to the trial team.

Trial monitoring {#Sec19}
----------------

A standard operating procedure defining the responsibilities, processes and deadlines for the monitoring of the ARA trial as well as a monitoring manual will be prepared. This is to ensure uniform monitoring of all the sites in the trial.

Clinical trial registration {#Sec20}
---------------------------

This trial is registered in the WHO International Clinical Trials Registry through the WHO International Registry Network (<https://pactr.samrc.ac.za/>: PACTR201806003040425).

Discussion {#Sec21}
==========

The findings of this proposed trial should provide evidence on the feasibility of applying conditional economic incentives combined with MI to improve retention and adherence to antiretroviral therapy of adolescents living with HIV in Nigeria and possibly in other sub-Saharan African countries.

We anticipate that enrolment of adolescents with HIV might be slow especially in HIV treatment hospitals with a low patient load. However, we included 12 HIV treatment hospitals that offer comprehensive HIV counselling and antiretroviral treatment services with good client load (including adolescents).

Trial status {#Sec22}
============

This is protocol version 1.0 as at 23 August 2018. Recruitment is planned to begin on 1 December 2018 and completed on 28 February 2019.

Additional files {#Sec24}
----------------

Additional file 1:Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist. (DOCX 20 kb) Additional file 2:Informed consent form (DOC 53 kb)

Appendix {#Sec23}
========

The following person are members of the Trial Steering Committee/Data and Safety Monitoring Board (DSMB):

Table 4Members of Steering Committee/DSMBNameJob descriptionInstitutionProf. PU EleProfessor of Internal Medicine; HIV focal person, NAUTHNnamdi Azikiwe University Teaching Hospital (NAUTH)Prof. OJ AfonneProfessor of PharmacologyNnamdi Azikiwe University Teaching Hospital (NAUTH)Dr. Raymond OkechukwuPharmacist with specialisation in HIV careNnamdi Azikiwe University Teaching Hospital (NAUTH)Prof. CO EsimoneProfessor of Pharmaceutical Microbiology and Biotechnology, Deputy Vice Chancellor or Nnamdi Azikiwe UniversityNnamdi Azikiwe University (NAU)Dr. GU ElejeConsultant in Obstetrics and GynaecologyNnamdi Azikiwe University Teaching Hospital (NAUTH)

AIDS

:   Acquired immunodeficiency syndrome

ART

:   Antiretroviral therapy

CEI

:   Conditional economic incentive

HIV

:   Human immunodeficiency virus

ICER

:   Incremental cost-effectiveness ratio

IDI

:   In-depth interview\`

MCH

:   Maternal and child health

MI

:   Motivational interviewing

NACA

:   National Agency for the Control of AIDS

NGN

:   Nigerian Naira

RCT

:   Randomised controlled trial

SPSS

:   Statistical Package for the Social Sciences

SSA

:   Sub-Saharan Africa

SURE-P

:   The Subsidy Reinvestment and Empowerment Programme

UCSF

:   The University of California, San Francisco

VL

:   Viral load

WHO

:   World Health Organisation

Not applicable.
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